Tăng Đường Huyết Sau Bữa Ăn ở Bệnh Nhân Đái Tháo Đường Loại 2

Jones DB, Gill GV. Non insulin dependent diabetes mellitus. In: Pickup J, Williams G, editors. Text book of diabetes mellitus. 2nd ed. London: Blackwell Sciences Ltd, 1997: 17.6–13

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53

Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23Suppl. 2: B21–9

Slama G. Clinical significance of post-prandial blood glucose excursions in Type 1 and Type 2 diabetes mellitus. Int J Clin. Pract Suppl 2000; 112: 9–12

Patel V, Rassam SM, Chen HC, et al. Oxygen reactivity in diabetes mellitus: effect of hypertension and hyperglycemia. Clin Sci (Lond) 1994; 86: 689–95

Sullivan PM, Davies GE, Caldwell G, et al. Retinal blood flow during hyperglycemia: a laser doppler velocimetry study. Invest Ophthalmol Vis Sci 1990; 31: 2041–5

Tuttle KR, Bruton JL, Perusek MC, et al.. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin dependent diabetes mellitus. N Engl J Med 1991; 324: 1626–32

Orskov L, Worm M, Schmitz O, et al. Nerve conduction velocity in man: influence of glucose, somatostatin and electrolytes. Diabetologia 1994; 37: 1216–20

Yeap BB, Russo A, Fraser RJ, et al. Hyperglycemia affects cardiovascular autonomic nerve function in normal subjects. Diabetes Care 1996; 19: 880–2

Teuscher A, Schnell H, Wilson PW. Incidence of diabetic retinopathy and relationship to baseline plasma glucose and blood pressure. Diabetes Care 1988; 11: 246–51

Hanefeld M, Temelkova-Kurktschiev T, Schaper F, et al. Impaired fasting glucose is not a risk factor for atherosclerosis. Diabet Med 1999; 16: 212–8

Donahue RP, Abbott RD, Reed DM, et al. Post challenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. Diabetes 1987; 36: 689–92

Jackson CA, Yudkin JS, Forrest RD. A comparison of the relationships of the glucose tolerance test and the glycated hemoglobin assay with diabetic vascular disease in the community: the Islington Diabetes Survey. Diabetes Res Clin Pract 1992; 17(2): 111–23

Jarrett RJ, McCartney P, Keen H. The Bedford Survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia 1982; 22: 79–84

Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11 year follow-up. Diabetologia 1996 39: 1577–83

de Vegt F, Dekker JM, Ruhe HG, et al. Hyperglycemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999; 42: 926–31

Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease: Paris Prospective Study. Diabetes Care 1991; 14: 461–9

Pyorala K, Savolainen E, Kaukola S, et al. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9½ year follow-up of the Helsinki Policemen Study population. Acta Med Scand Suppl 1985; 701: 38–52

Groot PH, van Stiphout WA, Krauss XH, et al. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb 1991; 11: 653–62

Patsch JR, Miesenbock G, Hopferweiser T, et al. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb 1992; 12: 1336–45

Ginsberg HN, Jones J, Blaner WS, et al. Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise: induced myocardial ischaemia in middle aged men and women. Arterioscler Thromb Vasc Biol 1995; 15: 1829–38

Habib MP, Dickerson FD, Mooradian AD. Effect of diabetes, insulin and glucose load on lipid peroxidation in the rat. Metabolism 1994; 43: 1442–5

Wehmeier KR, Mooradian AD. Autooxidative and antioxidative potential of simple carbohydrates. Free Radie Biol Med 1994; 17: 83–6

Mooradian AD, Habib MP, Dickerson F. Effect of simple carbohydrates, casein in hydrolysate and a lipid test meal on ethane exhalation rate. J Appl Physiol 1994; 76: 1119–22

Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycemia d. Drugs 1999; 57: 19–29

Del Prato S, Enzi G, Vigili de Kreutzenberg S, et al. Insulin regulation of glucose and lipid metabolism in massive obesity. Diabetologia 1990; 33: 228–36

Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non insulin dependent diabetes mellitus. N Engl J Med 1989; 321: 337–43

Gulli G, Ferrannini E, Stern M, et al. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican American NIDDM parents. Diabetes 1992; 41: 1575–86

Davies MJ, Rayman G, Grenfell A, et al. Loss of first phase insulin response to intravenous glucose in subjects with persistent impaired glucose tolerance. Diabet Med 1994; 11: 432–6

Kishimoto M, Yamasaki Y, Kubota M, et al. 1,5-Anhydro-D-glucitol evaluates daily glycemie excursions in well-controlled NIDDM. Diabetes Care 1995; 18: 1156–9

American Diabetes Association. Nutrition Recommendations and principles for people with diabetes mellitus. Diabetes Care 2000; 23Suppl. 1: S43–6

Balfour JA, McTavish D. Acarbose: an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993; 46: 1025–54

Clissold SP, Edwards C. Acarbose: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1988; 35(3): 214–43z

Hayakawa T, Kondo T, Okumura N, et al. Enteroglucagon release in disaccharide malabsorption induced by intestinal alpha-glucosidase inhibition. Am J Gastroenterol 1989; 84: 523–6

Jenkins DJ, Taylor RH, Goff DV, et al. Scope and specificity of acarbose in slowing carbohydrate absorption in man. Diabetes 1981; 30: 951–4

Couet C, Ulmer M, Hamdaoui M, et al. Metabolic effects of acarbose in young healthy men. Eur J Clin Nutr 1989; 43: 187–96

Hanefeld M, Fischer S, Schulze J, et al. Therapeutic potentials of acarbose as first line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991; 14: 732–7

Hotta N, Kakuta H, Sano T, et al. Long-term effect of acarbose on glycemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double blind study. Diabet Med 1993; 10: 134–8

Nestel PJ, Bazelmans J, Reardon MF, et al. Lower triglyceride production during carbohydrate-rich diets through acarbose, a glucoside hydrolase inhibitor. Diabete Metab 1985; 11: 316–7

Walter-Sack IE, Wolfram G, Zollner N. Effects of acarbose on serum lipoproteins in healthy individuals during prolonged administration of a fiber-free formula diet. Ann Nutr Metab 1989; 33: 100–7

Gerard J, Lefebvre PJ, Luyckx AS. Glibenclamide pharmacokinetics in acarbose-treated type 2 diabetics.Eur J Clin Pharmacol 1984; 27: 233–6

Scheen AJ, de Magalhaes AC, Salvatore T, et al. Reduction of acute bioavailability of metformin by the alpha-glucosidase inhibitor acarbose in normal man. Eur J Clin Invest 1994; 24Suppl. 3: 50–4

Johnston PS, Coniff RF, Hoogwerf BJ, et al. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 1994; 17: 20–9

Pagano G, Marena S, Corgiat-Mansin L, et al. Comparison of miglitol and glibenclamide in the diet-treated type 2 diabetic patients. Diabetes Metab 1995; 21: 162–7

Segal P, Feig PU, Schernthaner G, et al. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care 1997; 20: 687–91

Van Gaal L, Maislos M, Schernthaner G, et al. Miglitol combined with metformin improves glycemic control in Type 2 diabetes. Diabetes Obes Metab 2001; 3: 326–31

Gregorio F, Ambrosi F, Cristallini S, et al. Therapeutic concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A and B cell function. Diabetes Res Clin Pract 1992; 18: 197–206

Muller G, Hartz D, Punter J, et al. Differential interaction of glimepiride and glibenclamide with the beta cell sulfonylurea receptor: I. Binding characteristics. Biochim Biophys Acta 1994; 1191: 267–77

Kilo C, Dudley J, Kalb B. Evaluation of the efficacy and safety of Diamicron in non-insulin-dependent diabetic patients. Diabetes Res Clin Pract 1991; 14 Suppl.: S79–82

Noury J, Nandeuil A. Comparative three month study of the efficacies of metformin and gliclazide in the treatment of NIDD. Diabete Metab 1991; 17: 209–12

Kramer W, Muller G, Girbig F, et al. Differential interaction of glimepiride and glibenclamide with the beta cell sulfonylrea receptor. II. Photoaffinity labelling of a 65 kDA protein by [3H] glimepiride. Biochim Biophys Acta 1994; 1191: 278–90

Dills DG, Schneider J. Glimepiride/Glyburide Research Group. Clinical evaluation of glimepiride versus glyburide in NIDDM in double-blind comparative study. Horm Metab Res 1996; 28: 426–9

Draeger KE, Wernicke-Panten K, Lomp HJ, et al. Long term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double blind comparison with glibenclamide. Horm Metab Res 1996; 28: 419–25

Ladriere L, Malaisse-Lagae F, Fuhlendorff J, et al. Effect of antidiabetic agents on the increase in glycemia and insulinemia caused by refeeding in hereditarily diabetic rats. Res Commun Mol Pathol Pharmacol 1997; 97: 53–9

Landgraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs Aging 2000; 17: 411–25

Marbury TC, Runckle JL, Hatorp V, et al. Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 2000: 67: 7–15

Goldberg RB, Einhorn D, Lucas CP, et al. A double blind randomized comparison of meal related glycemic control by repaglinide and glyburide in well controlled type 2 diabetic patients. Diabetes Care 1999; 22: 789–94

Owens DR, Luzio SD, Ismail I, et al. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. Diabetes Care 2000; 23: 518–23

Wolffenbuttel BH, Nijst L, Sels JP, et al. Effects of a new oral hypoglycemic agent, repaglinide, on metabolic control in sulphonylurea treated patients with NIDDM. Eur J Clin Pharmacol 1993; 45: 113–6

Landgraf R, Bilo HJ, Muller PG. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol 1999; 55: 165–71

Wolffenbuttel BH, Landgraf A. A1-year multicenter randomized double blind comparison of repaglinide and glyburide for the treatment of Type 2 diabetes: Dutch and German Repaglinide Study Group. Diabetes Care 1999; 22: 463–7

Marbury T, Huang WC, Strange P, et al. Repaglinide versus glyburide: a one year comparison trial. Diabetes Res Clin Pract 1999; 43: 155–66

Madsbad S, Kolhovd B, Lager I, et al. Superior glycemie control with repaglinide compared with glipizide in type 2 diabetics. Diabetes 2000; 49: A1514

Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999; 22: 119–24

Damsbo P, Clauson P, Marbury TC, et al. A double blind randomized comparison of meal related glycemic control by repaglinide and glyburide in well controlled type 2 diabetic patients. Diabetes Care 1999; 22: 789–94

Hanefeld M, Bouter KP, Dickinson S, et al. Rapid and short acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000; 23: 202–7

Hirschberg Y, Karara AH, Pietri AO, et al. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin. Diabetes Care 2000; 23: 349–53

Marena S, Tagliaferro V, Montegrosso G, et al. Metabolic effects of metformin addition to chronic glibenclamide treatment in Type 2 diabetes. Diabete Metab 1994; 20: 15–9

Giugliano D, Quatraro A, Consoli G, et al. Metformin for obese, insulin treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993; 44: 107–12

Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in Type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001; 24: 710–9

Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with Type 2 diabetes. Diabetes Care 2000; 23: 1605–11

Berms DN, Alter LA, Beckage NJ, et al. Altering the association properties of insulin by amino acid replacement. Protein Eng 1992; 6: 527–33

Howey DC, Bowsher RR, Brunelle RL, et al. [Lys (B28), Pro (B29)] -human insulin: a rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396–402

Anderson Jr JH, Brunelle RL, Keohane P, et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non insulin dependent diabetes mellitus: Multicenter Insulin Lispro Study Group. Arch Intern Med 1997; 157: 1249–55

Gale EA. A randomized controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy: the UK Trial Group. Diabet Med 2000; 17: 209–14

Fineberg NS, Fineberg SE, Anderson JH, et al. Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes 1996; 45: 1750–4

Jovanovic L, Ilic S, Pettit DJ, et al. The metabolic and immunological effects of insulin lispro in gestational diabetes. Diabetes Care 1999; 22: 1422–7

Heinemann L, Heise T, Jorgensen LN, et al. Action profile of the rapid acting insulin analogue: human insulin B28 Asp. Diabet Med 1993; 10: 535–9

Home P, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 1999; 55: 199–203

Heise T, Weyer C, Serwas A, et al. Time-action profile of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 1998; 21: 800–3

Koivisto VA, Tuominen JA, Ebeling P. Lispro Mix 25 insulin as a premeal therapy in Type 2 diabetic patients. Diabetes Care 1999; 22: 459–62

Colombel A, Murat A, Krempf M, et al. Improvement of blood glucose control in Type 1 diabetic patients treated with lispro and multiple NPH injections. Diabet Med 1999; 16: 319–24

Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281; E155–61

Schmitz O, Nyholm B, Orskov L, et al. Effects of amylin and the amylin agonist pramlintide on glucose metabolism. Diabetes Med 1997; 14Suppl. 2: S19–23

Kong MF, King P, MacDonald IA, et al. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia 1997; 40: 82–8

Kolterman OG, Gottlieb A, Moyses C, et al. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC 137, a human amylin analogue. Diabetes Care 1995; 18: 1179–82

Thompson RG, Peterson J, Gotlieb A, et al. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes 1997; 46: 632–6